| Stiolto Respimat (olodaterol/tiotropium FDC) / Boehringer Ingelheim |
NCT02259959: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers |
|
|
| Completed | 1 | 36 | Europe | Single rising doses of BI 1744 CL, solution for oral inhalation, Tiotropium, fixed dose, solution for oral inhalation, Placebo | Boehringer Ingelheim | Healthy | 09/07 | | | |
NCT02231177: Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 1 | 47 | Europe | BI 1744 CL, BI 1744 CL/Tiotropium FDC, Tiotropium | Boehringer Ingelheim | Pulmonary Disease, Chronic Obstructive | 11/08 | | | |
NCT01703845: A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD. |
|
|
| Completed | 1 | 32 | Japan | Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol | Boehringer Ingelheim | Pulmonary Disease, Chronic Obstructive | 03/13 | 03/13 | | |
NCT02969317: Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients |
|
|
| Completed | 1 | 12 | RoW | Tiotropium, INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO, Olodaterol | Boehringer Ingelheim | Pulmonary Disease, Chronic Obstructive | 06/17 | 06/17 | | |
